The Cogora: The Agency team flew to Switzerland to support a client with a satellite symposium on ACC at the ESMO Sarcoma and Rare Cancers Congress.

The symposium was a great success, and the audience was very engaged. They are now developing the post-meeting report, which will capture all the discussions from the session, as well as the results from the evaluation form. 

It was also the first time that the client had the opportunity to present the newly designed product brochure, developed by Cogora, to their HCPs.

We have developed and finalised 3 deep dive articles on ‘The Challenge of Mycoplasma genitalium: Implications for Sexual Health’, ‘Molecular Testing for Gastrointestinal Parasites’ and ‘Molecular Testing for Chlamydia trachomatis and Neisseria gonorrhoeae’.

The HCM Academy 2025 Steering Committee meeting took place on Monday 10th March providing feedback to finalise the peer-to-peer CME workshop module and validating the four Country Leaders for onboarding. We now look to schedule the Train-the-trainer meeting to further develop.

Cogora: The Agency also ran a 3-hour virtual advisory board earlier this month looking at the challenges around the care pathway for both Alopecia areata and Atopic Dermatitis, as well as discussing findings from a Delphi survey. The meeting consisted of 9 HCPs and included dermatology consultants, specialist pharmacists as well as hearing the patient voice through the inclusion of PAGs. 

Planning is well underway for an advisory board taking place in Las Vegas next month ahead of INS. It will be a full day’s meeting with the objective being to understand the role and importance of needle-free connectors in reducing catheter-related complications. As well as the meeting, all faculty members will be taking part in pre interviews which will look to establish, amongst other things, the role and definition of NFCs.

The team have also run a Patient advisory board on insomnia. The meeting consisted of  6 UK based attendees and the purpose of the meeting was to gather insights into the education and support received by patients.

Check out what the team were up to in February for more examples of how Cogora: The Agency delivers consistent value for its clients. For more information, please contact us.

We are thrilled to announce that our HCM Academy programme has been shortlisted for ‘Most effective cross-channel campaign’ at The Dotties – awards showcasing marketing excellence.

HCM Academy is a free educational platform designed to support the timely diagnosis and optimal management of hypertrophic cardiomyopathy (HCM), a heart condition that affects as many as 1 in 200 people but is often under-diagnosed.  

The HCM Academy programme was developed by our CME division, PCM Scientific, in partnership with leading global experts, and with support from the steering committee and the Hypertrophic Cardiomyopathy Association (HCMA).

The campaign, designed to raise awareness about HCM, utilised a data-driven, multi-channel approach to engage healthcare professionals, including GPs, nurses, and cardiology teams across the US, Canada, UK, and Europe. 

Through targeted email, online advertising, social media, and event marketing, Cogora successfully drove a 200% increase in platform registrations and a 160% rise in user engagement. By tailoring messaging to the specific needs of different audiences, the campaign achieved impressive results, making a tangible impact on healthcare practices and patient outcomes.

The Dotties showcase marketing excellence across Dotdigital’s customer base. The winners will be announced at award ceremony on November 13^th in London.

The HCM Academy’s expert panel steering committee convened at ACC (American College of Cardiology) in Atlanta, GA, USA on Sunday, April 7th.

The PCMS team were onsite at the ACC to welcome and engage with our experts, discussing the results and insights from the interim analysis of the equality in healthcare survey distributed to our HCM Academy registered members, cardiologists and other HCPs in the US and Europe. Our steering committee members are some of the world leading figures in this therapeutic field – Martin Maron, Anjali Owens, Steve Ommen, and HCMA founder Lisa Salberg.

During the three-hour meeting, additional knowledge and key insights were gleaned and used to guide the next phase of our programme: the development of a consensus statement.

A significant takeaway from the meeting was the observation of minimal discrepancies between US and EU guidelines in practical terms. Where differences exist, there is often generally alignment between guidelines, and where obvious variances do occur, it is crucial to explore their implications for patients in practice.

Furthermore, discussion surrounded how individual patient background and origins might influence treatment choices, with further discussion around what constitutes the optimal approach for patient care. The aim for this phase of the program is to support greater diagnosis rates of HCM and better disease management that is equal for all, regardless of geography or patient population with an objective to support HCPs to:

• Recognise the disparities faced by specific underserved communities
• Encourage and drive access to a timely diagnosis and quality care for all patient populations

Our HCM Academy is a free CME initiative developed with renowned specialists that offers independent medical education, surrounding diagnosis and best practice aiming to improve patient outcomes by enhancing knowledge and confidence surrounding efficient diagnosis and management ofhypertrophic cardiomyopathy (HCM).

Running for over two years now, the programme has been developed in partnership with and endorsed by the HCMA. It is delivered to our community of primary and secondary care audiences including GPs, primary care nurses, cardiologists, interventional cardiologists, electrophysiologists, echocardiographers, and hospital pharmacists across the United States, Canada, and Europe, including the United Kingdom.

The primary and secondary care webinar series from 2023 is available on the HCM Academy website until November 2024 for HCPs to access and gain CE credit(s).

PCMS has successfully delivered the HCM Academy primary and secondary webinar series for 2023, now accessible on-demand via the HCM Academy website.

Brought to you by PCM Scientific, our CME division, the HCM Academy 2023 programme offers independent medical education, surrounding diagnosis and best practice care for patients with hypertrophic cardiomyopathy (HCM).

The primary and secondary care webinar series was accomplished with the support of our international faculty and steering committee members offering impactful education on diagnosis and best practice care and management of HCM.

The spectrum of topics covered was extensive, starting with fundamental ones like identifying HCM in primary care and progressing to an in-depth expert webinar aimed at aiding secondary healthcare professionals in understanding the detection and management of apical HCM.

The programme is developed in partnership with and endorsed by the HCMA, and was delivered to our community of primary and secondary care audiences including GPs, primary care nurses, cardiologists, interventional cardiologists, electrophysiologists, echocardiographers, and hospital pharmacists across the United States, Canada, and Europe, including the United Kingdom.

Engagement, learner feedback and education impact has been outstanding. 92% of attendees agreed they’ve gained knowledge that will ‘contribute to knowledge, skills, and attitude to enhance the delivery of patient care’ and 99% would recommend this education (event) to other healthcare providers.

The enduring assets are now available on the HCM Academy website until November 2024 for healthcare professionals to access and gain CE credit(s).